Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combined With Lenvatinib in ccRCC Patients With Liver Metastases
NCT07256223Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2026
- Primary completion
- Nov 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of envafolimab, lenvatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Fudan University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
envafolimablenvatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07256223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256223.